Corvus Pharmaceuticals (CRVS) Short-term Investments (2024 - 2026)

Corvus Pharmaceuticals' Short-term Investments history runs 3 years deep, the most recent figure standing at $196.6 million for Q1 2026.

• In Q1 2026, Short-term Investments changed N/A year-over-year to $196.6 million; the TTM figure through Mar 2026 stood at $196.6 million (changed N/A YoY), while the FY2025 annual figure was $52.2 million, up 20.71% from the prior year.
• Short-term Investments for Q1 2026 stood at $196.6 million, up from $52.2 million in the prior quarter.
• The five-year high for Short-term Investments was $196.6 million in Q1 2026, with the low at $43.2 million in Q4 2024.
• The 3-year median for Short-term Investments is $52.2 million (2025), against an average of $97.3 million.
• Peak annual rise in Short-term Investments reached 20.71% in 2025, while the deepest fall reached 20.71% in 2025.
• Corvus Pharmaceuticals' Short-term Investments stood at $43.2 million in 2024, then grew by 20.71% to $52.2 million in 2025, then surged by 276.84% to $196.6 million in 2026.
• Business Quant data shows CRVS's Short-term Investments at $196.6 million in Q1 2026, $52.2 million in Q4 2025, and $43.2 million in Q4 2024.